Volders, Pieter-Jan
Aftimos, Philippe
Dedeurwaerdere, Franceska
Martens, Geert
Canon, Jean-Luc
Beniuga, Gabriela
Froyen, Guy
Van Huysse, Jacques
De Pauw, Rebecca
Prenen, Hans
Lambin, Suzan
Decoster, Lore
Vaeyens, Freya
Rottey, Sylvie
Van Dam, Pieter-Jan
Decoster, Lynn
Rutten, Annemie
Schreuer, Max
Loontiens, Siebe
Van der Meulen, Joni
Mebis, Jeroen
Cuppens, Kristof
Tejpar, Sabine
Vanden Bempt, Isabelle
De Grève, Jacques
Schröder, David
van Marcke, Cédric
Van Den Bulcke, Marc
de Azambuja, Evandro
Punie, Kevin
Maes, Brigitte
Funding for this research was provided by:
European Commission (101080009, 101080009, 101080009, 101080009, 101080009)
Illumina
OncoDNA, Belgium
Velsera, USA
Belgian Society of Medical Oncologists
Article History
Received: 23 October 2024
Accepted: 3 March 2025
First Online: 10 March 2025
Competing interests
: Author P.A. declares a consultancy role with Boehringer Ingelheim, Roche, Novartis, Amcure, Servier, G1 Therapeutics, Radius, Deloitte, Daiichi Sankyo, Olema; honoraria from Synthon, Amgen, Novartis, Gilead, Lilly and Menarini; travel grants from Amgen, MSD, Pfizer, Roche, Daiichi Sankyo; research funding to his institution from Roche. Author K.P. declares speaker fees and/or honoraria for advisory/consultancy roles from Astra Zeneca, Eli Lilly, Exact Sciences, Focus Patient, Izidok, Medimix, Medscape, MSD, Mundi Pharma, Need Inc., Novartis, Pfizer, Hoffmann/La Roche, Sanofi and Seagen; travel grants from Astra Zeneca, Gilead Sciences, MSD, Novartis, Pfizer, PharmaMar and Hoffmann/La Roche. Author C.v.M. is a board member of BSMO but declares no personal financial competing interest. Author K.C. declares speaker fees and/or honoraria for advisory/consultancy roles from Amgen, Astra Zeneca, Bristol-Myers-Squibb, Daiichi Sankyo, Iteos therapeutics, Janssen, Merck Sharp Dohme, Pierre-Fabre Oncology. All other authors declare no financial or non-financial competing interests.